Literature DB >> 21063109

Palmitate-induced inhibition of insulin gene expression in rat islet β-cells involves the ceramide transport protein.

Jun Guo1, Jian Xi Zhu, Xia Heng Deng, Xiao Han Hu, Jie Zhao, Yu Jie Sun, Xiao Han.   

Abstract

Endogenous ceramide plays an important role in the palmitate (Palm) impairment of proinsulin gene expression in pancreatic islet β-cells. Changes in the liposoluble ceramide levels not only depend on metabolic enzymes but also on its transport to subcellular sites in response to Palm stimuli. In this study, we show that suppression of ceramide transport protein (CERT) mRNA with small interfering RNA contributed to intracellular ceramide accumulation in response to chronic Palm exposure and impairment of proinsulin gene expression, similar to the effect of inhibiting ceramide scavenging enzyme sphingomyelin synthase (SMS). High dose Palm treatment increased protein kinase D (PKD)-induced phosphorylation of CERT and its dysfunction. Intracellular accumulation of ceramide was associated with reduction of PDX-1 nuclear localization and MafA protein levels and stimulation of CCAAT/enhancer binding protein β (C/EBP β) expression. These conditions also corresponded with a reduction of PDX-1 and MafA and an increase of C/EBP β binding to the insulin promoter. Furthermore, down-regulation of C/EBP β could block ceramide impairment of proinsulin gene expression. The results reveal that Palm-mediated dysfunction of ceramide transport may contribute to intracellular ceramide accumulation and result in dysfunction of pancreatic beta cells by affecting binding of transcription factors to the insulin promoter.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21063109     DOI: 10.1159/000322339

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  8 in total

1.  Phosphoregulation of the ceramide transport protein CERT at serine 315 in the interaction with VAMP-associated protein (VAP) for inter-organelle trafficking of ceramide in mammalian cells.

Authors:  Keigo Kumagai; Miyuki Kawano-Kawada; Kentaro Hanada
Journal:  J Biol Chem       Date:  2014-02-25       Impact factor: 5.157

2.  Sphingolipid regulators of cellular dysfunction in Type 2 diabetes mellitus: a systems overview.

Authors:  Jessica S Ross; Sarah B Russo; Georgia C Chavis; Lauren A Cowart
Journal:  Clin Lipidol       Date:  2017-01-18

Review 3.  Role of ceramides in the pathogenesis of diabetes mellitus and its complications.

Authors:  Nawajes Mandal; Richard Grambergs; Koushik Mondal; Sandip K Basu; Faiza Tahia; Sam Dagogo-Jack
Journal:  J Diabetes Complications       Date:  2020-09-16       Impact factor: 2.852

4.  Early activation of nSMase2/ceramide pathway in astrocytes is involved in ischemia-associated neuronal damage via inflammation in rat hippocampi.

Authors:  LiZe Gu; BaoSheng Huang; Wei Shen; Li Gao; ZhengZheng Ding; HuiWen Wu; Jun Guo
Journal:  J Neuroinflammation       Date:  2013-09-03       Impact factor: 8.322

5.  Glucolipotoxicity impairs ceramide flow from the endoplasmic reticulum to the Golgi apparatus in INS-1 β-cells.

Authors:  Enida Gjoni; Loredana Brioschi; Alessandra Cinque; Nicolas Coant; M Nurul Islam; Carl K-Y Ng; Claudia Verderio; Christophe Magnan; Laura Riboni; Paola Viani; Hervé Le Stunff; Paola Giussani
Journal:  PLoS One       Date:  2014-10-28       Impact factor: 3.240

Review 6.  Natural Ligand-Mimetic and Nonmimetic Inhibitors of the Ceramide Transport Protein CERT.

Authors:  Kentaro Hanada; Shota Sakai; Keigo Kumagai
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

Review 7.  Roles of ceramide and sphingolipids in pancreatic β-cell function and dysfunction.

Authors:  Ebru Boslem; Peter J Meikle; Trevor J Biden
Journal:  Islets       Date:  2012 May-Jun       Impact factor: 2.694

Review 8.  Roles of Sphingolipid Metabolism in Pancreatic β Cell Dysfunction Induced by Lipotoxicity.

Authors:  Julien Véret; Lara Bellini; Paola Giussani; Carl Ng; Christophe Magnan; Hervé Le Stunff
Journal:  J Clin Med       Date:  2014-06-20       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.